Blood-based epigenome-wide analyses of cognitive abilities

Genome Biology

卷:23

Alison D. Murray¹  Daniel L. McCartney²  Robert F. Hillary²  Rosie M. Walker²  Riccardo E. Marioni²  Cliff Nangle²  Andrew M. McIntosh²  David J. Porteous²  Danni A. Gadd²  Archie Campbell²  Kathryn L. Evans²  Robin Flaig²  Elliot M. Tucker-Drob³  Daniel Trejo Banos⁴  Matthew R. Robinson⁵  Sarah E. Harris⁶  Susana Muñoz Maniega⁶  Eleanor L. S. Conole⁶  María del C. Valdés-Hernández⁶  Simon R. Cox⁶  Mathew A. Harris⁶  Ian J. Deary⁶  Mark E. Bastin⁶  Joanna M. Wardlaw⁶ 

[1] Aberdeen Biomedical Imaging Centre, University of Aberdeen;

[2] Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh;

[3] Department of Psychology, University of Texas;

[4] Department of Quantitative Biomedicine, University of Zurich;

[5] Institute of Science and Technology Austria;

[6] Lothian Birth Cohorts, Department of Psychology, University of Edinburgh;

关键词: DNA methylation;    EWAS;    Cognitive ability;    Prediction;    Epidemiology;   

DOI  :  10.1186/s13059-021-02596-5

来源: DOAJ

【 摘 要 】

Abstract Background Blood-based markers of cognitive functioning might provide an accessible way to track neurodegeneration years prior to clinical manifestation of cognitive impairment and dementia. Results Using blood-based epigenome-wide analyses of general cognitive function, we show that individual differences in DNA methylation (DNAm) explain 35.0% of the variance in general cognitive function (g). A DNAm predictor explains ~4% of the variance, independently of a polygenic score, in two external cohorts. It also associates with circulating levels of neurology- and inflammation-related proteins, global brain imaging metrics, and regional cortical volumes. Conclusions As sample sizes increase, the ability to assess cognitive function from DNAm data may be informative in settings where cognitive testing is unreliable or unavailable.

【 授权许可】

Unknown